圣湘生物
(688289)
| 流通市值：120.40亿 | | | 总市值：120.40亿 |
| 流通股本：5.88亿 | | | 总股本：5.88亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 390,946,762.39 | 1,007,118,933.74 | 632,543,388.93 | 427,695,798.2 |
| 营业收入 | 390,946,762.39 | 1,007,118,933.74 | 632,543,388.93 | 427,695,798.2 |
| 二、营业总成本 | 296,325,586.08 | 981,841,369.32 | 649,562,487.47 | 432,733,363.67 |
| 营业成本 | 73,904,097.3 | 286,640,893.23 | 197,785,471.82 | 142,251,745.56 |
| 税金及附加 | 2,358,171.97 | 4,646,049.09 | 1,727,637.98 | 2,386,214.38 |
| 销售费用 | 119,730,632.37 | 358,420,815.41 | 231,189,042.29 | 154,387,810.7 |
| 管理费用 | 61,961,457.17 | 189,312,341.1 | 122,390,928.98 | 75,773,373.91 |
| 研发费用 | 55,402,242.13 | 196,275,570.41 | 137,493,724.89 | 90,521,955.62 |
| 财务费用 | -17,031,014.86 | -53,454,299.92 | -41,024,318.49 | -32,587,736.5 |
| 其中:利息费用 | 5,387,422.13 | 2,408,602.59 | 908,881.11 | 207,881.76 |
| 其中:利息收入 | 22,698,184.23 | 54,672,883.49 | 35,982,498.15 | 22,874,248.13 |
| 加:公允价值变动收益 | 2,975,320.32 | 61,842,500.27 | 60,572,951.28 | 48,064,430.84 |
| 加:投资收益 | -16,888,538.69 | 253,737,455.45 | 241,992,279.47 | -12,577,064.62 |
| 资产处置收益 | -63,499.97 | -247,879.07 | -85,490.12 | -301,220.26 |
| 资产减值损失(新) | 4,399,418.72 | 7,506,807.73 | 890,367.44 | 121,887.44 |
| 信用减值损失(新) | 1,714,609.02 | -446,864.34 | 14,092,317.24 | 16,494,678.41 |
| 其他收益 | 10,061,490.1 | 79,793,338.22 | 65,887,828.26 | 64,612,620.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 96,819,975.81 | 427,462,922.68 | 366,331,155.03 | 111,377,767.24 |
| 加:营业外收入 | 108,782.06 | 1,518,902.91 | 1,460,011.99 | 1,277,603.6 |
| 减:营业外支出 | 4,596,366.91 | 18,503,647.24 | 15,668,024.07 | 4,609,702.87 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 92,332,390.96 | 410,478,178.35 | 352,123,142.95 | 108,045,667.97 |
| 减:所得税费用 | 18,922,099.9 | 62,310,821.36 | 53,638,063.19 | 17,124,934.12 |
| 六、净利润 | 73,410,291.06 | 348,167,356.99 | 298,485,079.76 | 90,920,733.85 |
| 持续经营净利润 | 73,410,291.06 | 348,167,356.99 | 298,485,079.76 | 90,920,733.85 |
| 归属于母公司股东的净利润 | 81,024,703.84 | 363,721,131.71 | 299,723,558.25 | 91,676,113.08 |
| 少数股东损益 | -7,614,412.78 | -15,553,774.72 | -1,238,478.49 | -755,379.23 |
| (一)基本每股收益 | 0.14 | 0.62 | 0.51 | 0.16 |
| (二)稀释每股收益 | 0.14 | 0.62 | 0.51 | 0.16 |
| 八、其他综合收益 | 1,916,849.56 | -144,495,170.71 | -8,530,070.97 | 3,757,379.64 |
| 归属于母公司股东的其他综合收益 | 1,916,849.56 | -134,150,880.42 | -7,823,632.07 | 334,134.94 |
| 九、综合收益总额 | 75,327,140.62 | 203,672,186.28 | 289,955,008.79 | 94,678,113.49 |
| 归属于母公司股东的综合收益总额 | 82,941,553.4 | 229,570,251.29 | 291,899,926.18 | 92,010,248.02 |
| 归属于少数股东的综合收益总额 | -7,614,412.78 | -25,898,065.01 | -1,944,917.39 | 2,667,865.47 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-31 | 2023-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |